BNP
[BNP]
EPTIS Ringversuch Nr. 142554 | Letze Änderung 2024-09-24 | URL: https://www.eptis.bam.de/pts142554 https://www.eptis.bam.de/pts142554
| Name des Anbieters | |||||||||||||
| Name des Anbieters | Weqas Weqas | ||||||||||||
| Ansässig in | United Kingdom | ||||||||||||
| Sprache(n) | |||||||||||||
| Anmerkungen | Natriuretic peptide testing – B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) is an important tool for rapidly assessing adults presenting with new suspected acute heart failure. Participants can enrol in the programme most appropriate to their testing method and analyte i.e. laboratory methods for BNP, NT-proBNP or point of care testing (PoCT). Separate samples are provided for BNP and NT-proBNP. PoCT devices are assessed separately to laboratory methods. Three samples covering the appropriate physiological and pathological range including challenging samples near the diagnostic thresholds are distributed bimonthly. The base material for BNP is human EDTA plasma and for NT-proBNP lithium heparin plasma to reflect the preferred sample type used for patient testing. The samples consist of a panel of linearly related samples produced from donations from healthy volunteers spiked with natriuretic peptides. Recombinant human BNP-32 and NT-proBNP respectively are added, with the addition of protease inhibitors to improve stability. For BNP the samples are dispatched by Courier on dry ice, however, multiple distributions can be dispatched in one shipment to minimise costs. Key Features: - Surrogate, clinically appropriate samples at diagnostic thresholds. - Suitable for both Laboratory and PoCT analysers. - Preferred sample type – EDTA plasma or Lithium Heparin plasma. - Linearly related panel covering a clinically relevant range. - Liquid human serum samples require no pre-analytical preparation. For more information: https://www.weqas.com/services/eqa/bnp/ or contact@weqas.com | ||||||||||||
| Klassifizierung | |||||||||||||
| Produktgruppen |
Health care / medical devices
|
||||||||||||
| Prüfgebiete |
Medical analysis
|
||||||||||||
| Technische Einzelheiten | |||||||||||||
|
|||||||||||||
| Ringversuchsziele | |||||||||||||
| Zielgruppe des Ringversuchs | Suitable for both Laboratory and POCT analysers. | ||||||||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS based on ISO/IEC 17043. | ||||||||||||
| Weitere Ziele | validation of testing methods | ||||||||||||
| Teilnehmerzahl | |||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 |
||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | |||||||||||||
| Kosten | |||||||||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | ||||||||||||
| Regelmässig durchgeführt | Ja (Frequency: Bimonthly. Samples: 3 x 0.5mL.) | ||||||||||||
| Der Ringversuch wird durchgeführt seit | 2005 | ||||||||||||
| Kontaktdaten des Anbieters | |||||||||||||
| Anbieter | Kontaktperson | ||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.